DLBCL

Cost-effective lymphoma treatment for developing countries

L:

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, Matthew Painschab from The University of North Carolina, Chapel Hill, US discussed data he carried out in collaboration with the Malawi Ministry of Health.

Dr. Painschab discusses the abstracted presented at ASCO 2019, combining a cost-effective model of the effectiveness of treatments of diffused large B cell lymphoma, with CHOP chemotherapy, as well as micro-costing data that can be combined into a decision tree for analysis. Dr. Painschab emphasized that the investigators found that based on real-life treatment data of a cohort treated with CHOP chemotherapy, the cost per disability-adjusted life year is around $200, this remained significant in about 95% of simulations.